Developer docs
API playgroundTry for free, no card

Search company profiles

AiBiologics

Full company profile

uuid000wdy7

Namestring
AiBiologics
Websiteurl
aibiologics.ie
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

AiBiologics is a Dublin-based biotech that applies AI and deep learning to epitope prediction for biopharmaceutical, diagnostic, and vaccine discovery, anchored by its proprietary EpitopePredikt technology and serving life-sciences research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epitope prediction, AI drug discovery, biopharmaceutical AI, vaccine discovery, deep learning biology
Industry4 codes
1AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
CodeHLAAAIAEPrimaryYes
2Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
CodeHLAAAIABPrimaryNo
3AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryNo
4Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
CodeHLAAALAOPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Prepackaged Software7372
Product category
AI-driven Drug Discovery Software
Social media profiles1 record
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

AiBiologics is a biotechnology firm that develops and applies AI and deep learning algorithms to revolutionize biopharmaceutical, diagnostic, and vaccine discovery. Its core offering is the proprietary EpitopePredikt technology, an epitope prediction and analysis platform used to identify and analyze epitopes for biotechnology and pharmaceutical applications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1EpitopePredikt
CategoryEpitope prediction / computational biology software
No data
Peers10 records
1Absci
TypeDirect peer
Description

Generative AI drug creation platform with a focus on de novo antibody design. Comparable to AiBiologics as an AI-first biologics discovery company targeting pharma partners, with overlapping customer base and technology stack.

2Schrödinger
TypeBroad incumbent
Description

Established computational chemistry and biology platform serving pharma R&D. Comparable as a broader AI-for-molecular-discovery incumbent with overlapping customer base in biopharma, though operating at much greater scale and scope.

3Generate Biomedicines
TypeDirect peer
Description

Generative biology platform for programmable biologics across multiple therapeutic areas. Comparable as an AI-driven biologics discovery company spanning multiple disease and modality areas.

4BenchSci
TypeEmerging player
Description

AI platform that helps biopharma R&D teams select reagents and interpret experimental data. Comparable as an AI-software-for-biotech company targeting the same pharma R&D buyer persona, although focused on reagent intelligence rather than epitope prediction.

5Recursion Pharmaceuticals
TypeBroad incumbent
Description

AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable in applying AI to early-stage biopharma discovery, though with proprietary pipeline ambitions rather than pure platform plays.

6BigHat Biosciences
TypeDirect peer
Description

AI/ML-guided antibody design and engineering platform combining wet-lab validation with computational design. Directly comparable in using AI to optimise biologics — particularly antibodies — for pharmaceutical applications.

7AbCellera Biologics
TypeDirect peer
Description

AI-driven antibody discovery platform combining high-throughput screening with machine learning. Directly comparable as a tech-enabled antibody/biologics discovery company competing for pharma partnerships in epitope and antibody engineering.

8Cradle Bio
TypeEmerging player
Description

AI platform for protein engineering using generative models. Comparable to AiBiologics as an early-stage AI-for-biologics company, although focused more broadly on protein design rather than epitope-specific prediction.

9Atomic AI
TypeEmerging player
Description

AI-driven RNA structure prediction company bridging computational biology with therapeutics. Comparable as an emerging AI-biotech applying deep learning to structural biology questions relevant to biologics design.

10Insilico Medicine
TypeBroad incumbent
Description

AI-driven drug discovery company spanning target identification, small molecules and biologics. Comparable as an AI-bio incumbent with overlapping interest in biologics and antibody-related discovery workflows.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AiBiologics

AI-driven Drug Discovery Softwareaibiologics.ie

AiBiologics is a Dublin-based biotech that applies AI and deep learning to epitope prediction for biopharmaceutical, diagnostic, and vaccine discovery, anchored by its proprietary EpitopePredikt technology and serving life-sciences research customers.

AiBiologics firmographics

Firmographics
Name
AiBiologics
Website
https://aibiologics.ie
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AiBiologics is a Dublin-based biotech that applies AI and deep learning to epitope prediction for biopharmaceutical, diagnostic, and vaccine discovery, anchored by its proprietary EpitopePredikt technology and serving life-sciences research customers.
Ownership category
akta.pro rank

AiBiologics industry classification

Industry
Product category
AI-driven Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Prepackaged Software (7372)
akta.pro primary industry
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
akta.pro secondary industries
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

  • Epitope prediction
  • AI drug discovery
  • Biopharmaceutical AI
  • Vaccine discovery
  • Deep learning biology

Where AiBiologics is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

AiBiologics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Distribution channels1 record

AiBiologics product offering

Product offering

Core offering

AiBiologics is a biotechnology firm that develops and applies AI and deep learning algorithms to revolutionize biopharmaceutical, diagnostic, and vaccine discovery. Its core offering is the proprietary EpitopePredikt technology, an epitope prediction and analysis platform used to identify and analyze epitopes for biotechnology and pharmaceutical applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • EpitopePredikt

Companies that use AiBiologics

Customer profile

Ideal customer profiles1 record

AiBiologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

AiBiologics competitors and assessment

Company assessment

Direct peers

  • Absci: Generative AI drug creation platform with a focus on de novo antibody design. Comparable to AiBiologics as an AI-first biologics discovery company targeting pharma partners, with overlapping customer base and technology stack.
  • Generate Biomedicines: Generative biology platform for programmable biologics across multiple therapeutic areas. Comparable as an AI-driven biologics discovery company spanning multiple disease and modality areas.
  • BigHat Biosciences: AI/ML-guided antibody design and engineering platform combining wet-lab validation with computational design. Directly comparable in using AI to optimise biologics — particularly antibodies — for pharmaceutical applications.
  • AbCellera Biologics: AI-driven antibody discovery platform combining high-throughput screening with machine learning. Directly comparable as a tech-enabled antibody/biologics discovery company competing for pharma partnerships in epitope and antibody engineering.

Broad incumbents

  • Schrödinger: Established computational chemistry and biology platform serving pharma R&D. Comparable as a broader AI-for-molecular-discovery incumbent with overlapping customer base in biopharma, though operating at much greater scale and scope.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable in applying AI to early-stage biopharma discovery, though with proprietary pipeline ambitions rather than pure platform plays.
  • Insilico Medicine: AI-driven drug discovery company spanning target identification, small molecules and biologics. Comparable as an AI-bio incumbent with overlapping interest in biologics and antibody-related discovery workflows.

Emerging players

  • BenchSci: AI platform that helps biopharma R&D teams select reagents and interpret experimental data. Comparable as an AI-software-for-biotech company targeting the same pharma R&D buyer persona, although focused on reagent intelligence rather than epitope prediction.
  • Cradle Bio: AI platform for protein engineering using generative models. Comparable to AiBiologics as an early-stage AI-for-biologics company, although focused more broadly on protein design rather than epitope-specific prediction.
  • Atomic AI: AI-driven RNA structure prediction company bridging computational biology with therapeutics. Comparable as an emerging AI-biotech applying deep learning to structural biology questions relevant to biologics design.

Market position

Customer concentration

AiBiologics social profiles

Digital presence

AiBiologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AiBiologics leadership team

Management profile

Number of profiles

AiBiologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AiBiologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiBiologics

What does AiBiologics do?

AiBiologics is a biotechnology firm that develops and applies AI and deep learning algorithms to revolutionize biopharmaceutical, diagnostic, and vaccine discovery. Its core offering is the proprietary EpitopePredikt technology, an epitope prediction and analysis platform used to identify and analyze epitopes for biotechnology and pharmaceutical applications.

When was AiBiologics founded?

AiBiologics was founded in 2019. It employs 11 to 50 people.

Where is AiBiologics based?

AiBiologics is headquartered in Dublin, Ireland, in the Europe region.

Who are AiBiologics's main competitors?

Direct peers on record are Absci, Generate Biomedicines, BigHat Biosciences and AbCellera Biologics. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Insilico Medicine. Emerging players are BenchSci, Cradle Bio and Atomic AI.

Does AiBiologics have an API?

No public API is recorded for AiBiologics.

What industry is AiBiologics in?

AiBiologics's product category is AI-driven Drug Discovery Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales